Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
Business Wire•10/11/2026•08:00 ET
0
Key Highlights
- ➤Agilent launches SureSelect Cancer Research Pan Heme for hematologic malignancy profiling
- ➤Pan Heme interrogates 359 DNA and 124 RNA genes
- ➤Solution detects SNVs, indels, CNVs, immunoglobulin translocations, and gene fusions
- ➤Roswell Park implementation delivers integrated sample-to-report results in approximately 48 hours
- ➤Workflow supports automated, manual, and semiautomated configurations for research laboratories
Expert Statements
Majken Nielsen, Vice president and general manager of Agilent's Clinical Diagnostics Division
“Researchers studying hematologic malignancies need comprehensive genomic information while also managing increasingly complex laboratory workflows”
Majken Nielsen, Vice president and general manager of Agilent's Clinical Diagnostics Division
“SureSelect Cancer Research Pan Heme brings together DNA and RNA profiling, walkaway automation and analysis in an integrated research workflow, helping laboratories generate deeper molecular insights while reducing hands-on demands and simplifying the path from sample to results.”
Sean Glenn, Vice chair of molecular pathology at Roswell Park Comprehensive Cancer Center
“Hematologic malignancies are incredibly complex, and gaining a comprehensive view often requires looking at both DNA and RNA”
Sean Glenn, Vice chair of molecular pathology at Roswell Park Comprehensive Cancer Center
“We’ve been able to combat these limitations with Agilent to streamline comprehensive genomic profiling into an efficient automated workflow, providing insights in about 48 hours. We’re excited to see this workflow become available to researchers to help simplify and democratize a robust molecular profiling solution for hematologic cancer research.”
Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
Integrated DNA and RNA profiling solution developed in collaboration with Roswell Park Comprehensive Cancer Center
Get started
Create a free account to read the full story.